<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9867">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05688488</url>
  </required_header>
  <id_info>
    <org_study_id>2022011-1</org_study_id>
    <nct_id>NCT05688488</nct_id>
  </id_info>
  <brief_title>Clinical Study of Curcumin in Preventing Postoperative Adhesion of Bilateral Vocal Cords</brief_title>
  <official_title>Clinical Study of Curcumin in Preventing Postoperative Adhesion of Bilateral Vocal Cords</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eye &amp; ENT Hospital of Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eye &amp; ENT Hospital of Fudan University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To provide a novel therapy idea and method to solve the clinical problem of postoperative&#xD;
      adhesion of bilateral vocal cords, patients enrolled in this study will be applied with&#xD;
      curcumin on both wound sites of bilateral vocal cords after the surgery on the bilateral&#xD;
      vocal cord endoscopically.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">May 5, 2023</start_date>
  <completion_date type="Anticipated">December 31, 2026</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2025</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with laryngeal web formation as assessed by videolaryngoscope</measure>
    <time_frame>1 year postsurgery</time_frame>
    <description>All participants received the videolaryngoscope every month post-surgery, and a laryngeal web is defined as a visible adhesion whose length reached 1 mm or greater.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Glottic Web of Larynx</condition>
  <condition>Laryngeal Stenosis</condition>
  <condition>Glottic Carcinoma</condition>
  <condition>Laryngeal Leucoplakia</condition>
  <condition>Laryngeal Polyp</condition>
  <condition>Laryngeal Papilloma</condition>
  <arm_group>
    <arm_group_label>Curcumin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Mitomycin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Curcumin</intervention_name>
    <description>Curcumin was applied to both wound sites of bilateral vocal cords. After evenly applied, gently massage the applied site for 3-5 minutes until the drug was fully absorbed.</description>
    <arm_group_label>Curcumin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mitomycin-C</intervention_name>
    <description>Mitomycin-C was applied to both wound sites of bilateral vocal cords. After evenly applied, gently massage the applied site for 3-5 minutes until the drug was fully absorbed.</description>
    <arm_group_label>Mitomycin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with bilateral vocal cord diseases who are going to undergo resection of&#xD;
             bilateral vocal cord lesions endoscopically.&#xD;
&#xD;
          2. Patients with bilateral vocal cord adhesion who are going to undergo incision of&#xD;
             bilateral vocal cord adhesion endoscopically.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with other laryngeal diseases.&#xD;
&#xD;
          2. Patients with cardiac and pulmonary insufficiency.&#xD;
&#xD;
          3. Patients unable to cooperate with the follow-up on time after surgery.&#xD;
&#xD;
          4. Patients who refuse to sign the informed consent after notification.&#xD;
&#xD;
          5. Patients who have a severe allergic disease or allergic history to a variety of drugs.&#xD;
&#xD;
          6. Other circumstances that are not appropriate to be included in the clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jian Chen, Ph.D</last_name>
    <phone>+8621-64377134</phone>
    <email>chenjent@qq.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Haitao Wu, Ph.D</last_name>
    <phone>+8621-64377134</phone>
    <email>eentwuhaitao@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Eye &amp; ENT Hospital of Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200031</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jian Chen</last_name>
      <email>chenjent@qq.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2023</verification_date>
  <study_first_submitted>December 28, 2022</study_first_submitted>
  <study_first_submitted_qc>January 15, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">January 18, 2023</study_first_posted>
  <last_update_submitted>May 5, 2023</last_update_submitted>
  <last_update_submitted_qc>May 5, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">May 6, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Curcumin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Papilloma</mesh_term>
    <mesh_term>Leukoplakia</mesh_term>
    <mesh_term>Laryngostenosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Curcumin</mesh_term>
    <mesh_term>Mitomycins</mesh_term>
    <mesh_term>Mitomycin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

